CAS 496775-62-3

Eltrombopag olamine

Description:

Eltrombopag olamine is a synthetic small molecule that acts as a thrombopoietin receptor agonist, primarily used in the treatment of thrombocytopenia, particularly in patients with chronic immune thrombocytopenic purpura (ITP) and those undergoing certain types of chemotherapy. Its chemical formula includes elements such as carbon, hydrogen, nitrogen, and oxygen, reflecting its complex organic structure. Eltrombopag olamine enhances platelet production by stimulating the megakaryocyte lineage in the bone marrow, thereby increasing platelet counts. The compound is typically administered orally and is characterized by its moderate solubility in water, which can influence its bioavailability. Eltrombopag olamine has a relatively long half-life, allowing for once-daily dosing in clinical settings. As with many pharmaceuticals, it may have side effects, including potential liver enzyme elevations and thromboembolic events, necessitating regular monitoring during treatment. Overall, Eltrombopag olamine represents a significant advancement in managing conditions associated with low platelet counts.

Formula: C₂₅H₂₂N₄O₄·2C₂H₇NO

InChI: InChI=1S/C25H22N4O4.C2H7NO/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33;3-1-2-4/h4-13,26,30H,1-3H3,(H,32,33);4H,1-3H2/b27-22-;

InChI key: InChIKey=LQQUHOUXABUDJA-OUFJFOJPSA-N

SMILES: O=C/1N(N=C(C)\C1=N\NC2=C(O)C(=CC=C2)C3=CC(C(O)=O)=CC=C3)C4=CC(C)=C(C)C=C4.C(CO)N

Synonyms:

• (1,1'-Biphenyl)-3-carboxylic acid, 3'-((2Z)-(1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene)hydrazino)-2'-hydroxy-, compound with 2-aminoethanol (1:2)
• 3'-((2Z)-2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene)diazanyl)-2'-hydroxybiphenyl-3-carboxylic acid compound with 2-aminoethanol (1:2)
• Eltrombopag Olamine [USAN]
• Eltrombopag diethanolamine salt
• Promacta
• Revolade
• Sb 497115Gr
• Sb-497115-Gr
• Unii-4U07F515Lg
• [1,1′-Biphenyl]-3-carboxylic acid, 3′-[(2Z)-2-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2′-hydroxy-, compd. with 2-aminoethanol (1:2)
• [1,1′-Biphenyl]-3-carboxylic acid, 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-, compd. with 2-aminoethanol (1:2)

Eltrombopag Olamine

CAS: 496775-62-3

Formula: C₂₅H₂₂N₄O₄·2C₂H₇NO

Color and Shape: Dark Red Solid

Molecular weight: 442.48 2*61.08

Ref: 4Z-E-483

Revolade

CAS: 496775-62-3

Revolade

Purity: 99%

Molecular weight: 564.64g/mol

Ref: 54-OR1024595

Eltrombopag Olamine

CAS: 496775-62-3

Eltrombopag Olamine

Purity: ≥98%

Molecular weight: 564.63g/mol

Ref: 54-BUP17133

Eltrombopag Olamine

CAS: 496775-62-3

Color and Shape: Neat

Ref: 86-MM3970.00

Eltrombopag Olamine

CAS: 496775-62-3

Eltrombopag Olamine (Eltrombopag diethanolamine salt) is the orally active ethanolamine salt of eltrombopag, a small-molecule, nonpeptide thrombopoietin

Formula: C₂₉H₃₆N₆O₆

Purity: 99.59% - 99.89%

Color and Shape: Solid

Molecular weight: 564.63

Ref: TM-T6825

Eltrombopag Olamine

CAS: 496775-62-3

Stability Hygroscopic
Applications Eltrombopag is an agonist of the Thrombopoietin (Tpo) receptor, used as treatment for thrombocytopenia
Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package
References Bussel, J., et al.: New Eng. J. Med., 357, 2237 (2007), Marsilje, T., et al.: Bioorg. Med. Chem. Lett., 18, 5259 (2008), Alper, P., et al.: Bioorg. Med. Chem. Lett., 18, 5255 (2008)

Formula: C₂₅H₂₂N₄O₄·2C₂H₇NO

Color and Shape: Dark Red

Molecular weight: 564.63

Ref: TR-E508100

Eltrombopag olamine

CAS: 496775-62-3

Eltrombopag olamine is an orally active drug that belongs to the class of thiazolidinones. It has been used for the treatment of thrombocytopenia in patients with chronic liver disease and myelodysplastic syndrome. Eltrombopag olamine inhibits platelet aggregation by binding to glycoprotein IIb/IIIa receptors on the surface of platelets. The drug is a prodrug that is metabolized in vivo to its active form, eltrombopag. This conversion is catalysed by CYP3A4 and CYP2D6 enzymes and can be inhibited by drugs that inhibit these enzymes, such as trifluoroacetic acid and hydroxyl group-containing compounds. Eltrombopag olamine binds to erythrocytes, which may be due to its ability to form intramolecular hydrogen bonds with nitrogen atoms. The synthesis of elt

Formula: C₂₅H₂₂N₄O₄•(C₂H₇NO)₂

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 564.63 g/mol

Ref: 3D-FD157443